Onyx Pharmaceuticals (NASDAQ: [[ticker:ONXX]]) is moving its headquarters from Emeryville, CA to a space in South San Francisco vacated by Exelixis, according to this report in the San Francisco Business Times. Onyx, which co-markets the hit cancer drug sorafenib (Nexavar), plans to move 220 employees to the facility at 249 E. Grand Avenue, according to the newspaper. The space was freed up after Exelixis cut about 270 jobs at its South San Francisco headquarters in March.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
